Gapping up
In reaction to strong earnings/guidance:
- ZS +19.9% (also acquires Edgewise Networks), BIG +13.6%, GLUU +9.4%, VMW +8.2%, WSM +8%, DELL +7.2%, MRVL +6%, PAGS +4.7%, PSTG +3.9%, OLLI +2.8%
Other news:
- PRTY +88.2% (executes Transaction Support Agreement with bondholders holding over $440 mln of its bonds)
- TLSA +5.1% (presents data demonstrating StemPrintER outperforms Oncotype DX)
- ADAP +3.9% (presented updated data from its ADP-A2M4 Phase 1 trial at ASCO)
- AZN +3.7% (announces positive Phase III ADAURA trial results)
- KPTI +3.7% (reports results from the pivotal, Phase 3 BOSTON study )
- PCG +3.6% (receives approval for Chapter 11 Plan of Reorganization from CPUC)
- MRSN +2.7% (prices offering of 8 mln shares of common stock at $19.00 per share)
- CSCO +1.7% (to acquire privately held ThousandEyes)
- ALCO +1.7% (Florida has option to purchase 10,684 acres)
- GSX +1.6% (refutes allegations in Muddy Waters Research report)
- LGND +1.4% (earns $3 mln milestone payment from Palvella Therapeutics)
- NVS +1.2% (receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation)
- LLY +1.1% (receives FDA approval of TAUVID)
Analyst comments:
- CULP +13.4% (upgraded to Buy from Hold at Stifel)
- KL +2.6% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- BLMN +1.8% (upgraded to Buy from Hold at Jefferies)
- RIO +1.7% (upgraded to Buy at BofA/Merrill), PPL +1.5% (upgraded to Buy from Neutral at Mizuho)